{"id":"inhaled-loxapine","safety":{"commonSideEffects":[{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Dysarthria"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Extrapyramidal symptoms"},{"rate":null,"effect":"Throat irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Loxapine is a dibenzoxazepine antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. The inhaled formulation delivers the drug directly to the lungs for rapid systemic absorption, enabling faster onset of action compared to oral formulations, making it suitable for acute agitation management in psychiatric settings.","oneSentence":"Inhaled loxapine is a rapid-acting antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce acute agitation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:30.999Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute agitation associated with schizophrenia or bipolar disorder"}]},"trialDetails":[{"nctId":"NCT03513549","phase":"","title":"Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder","status":"SUSPENDED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2014-11-04","conditions":"Agitation,Psychomotor","enrollment":10000},{"nctId":"NCT00610727","phase":"PHASE1","title":"Staccato Prochlorperazine Single Dose PK Study","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2004-08","conditions":"Migraine","enrollment":54},{"nctId":"NCT02504450","phase":"","title":"Outcomes of Antipsychotic Medication Used in the Emergency Department","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2015-04","conditions":"Agitation,Psychomotor","enrollment":93},{"nctId":"NCT02184767","phase":"PHASE1","title":"Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"BiPolar","enrollment":30},{"nctId":"NCT02525991","phase":"PHASE4","title":"Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting","status":"COMPLETED","sponsor":"Ferrer Internacional S.A.","startDate":"2016-09-08","conditions":"Agitation","enrollment":323},{"nctId":"NCT04148963","phase":"PHASE3","title":"A Study of Staccato Loxapine (ADASUVE®) for Inhalation","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2019-12-01","conditions":"Psychomotor Agitation, Schizophrenia, Bipolar Disorder","enrollment":150},{"nctId":"NCT00874237","phase":"PHASE1","title":"Staccato Loxapine Thorough QT/QTc Study","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2009-04","conditions":"Thorough QT/QTc Study","enrollment":48},{"nctId":"NCT00789360","phase":"PHASE1","title":"Staccato Loxapine Pulmonary Safety in Healthy Volunteers","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2008-11","conditions":"Healthy","enrollment":30},{"nctId":"NCT00543062","phase":"PHASE1","title":"Staccato Prochlorperazine Thorough QT/QTc","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2007-10","conditions":"Cardiotoxicity","enrollment":48},{"nctId":"NCT00444028","phase":"PHASE1","title":"Staccato Loxapine Single Dose PK","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2005-09","conditions":"Schizophrenia","enrollment":50},{"nctId":"NCT03110900","phase":"PHASE4","title":"Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2017-09-30","conditions":"Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use","enrollment":2},{"nctId":"NCT00369577","phase":"PHASE2","title":"Staccato Loxapine in Agitation (Proof of Concept)","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2006-08","conditions":"Schizophrenia","enrollment":129},{"nctId":"NCT01877642","phase":"PHASE4","title":"ADASUVE-Lorazepam Drug-Drug Interaction","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2013-06","conditions":"Healthy Volunteers","enrollment":22},{"nctId":"NCT01854710","phase":"PHASE4","title":"ADASUVE 2-dose Thorough QT/QTc Study","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2013-05","conditions":"Healthy Volunteers","enrollment":60},{"nctId":"NCT00628589","phase":"PHASE3","title":"Staccato Loxapine in Agitated Patients With Schizophrenia","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2008-02","conditions":"Patients With Schizophrenia and Acute Agitation","enrollment":344},{"nctId":"NCT00721955","phase":"PHASE3","title":"Staccato Loxapine in Agitated Patients With Bipolar Disorder","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2008-07","conditions":"Bipolar I Disorder","enrollment":314},{"nctId":"NCT00489476","phase":"PHASE2","title":"Staccato Loxapine in Migraine (in Clinic)","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2007-06","conditions":"Migraine","enrollment":168},{"nctId":"NCT00825500","phase":"PHASE2","title":"Staccato Loxapine in Migraine (Out Patient)","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2009-01","conditions":"Migraine Headache","enrollment":366},{"nctId":"NCT00555412","phase":"PHASE1","title":"Staccato Loxapine Multidose PK","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2007-10","conditions":"Volunteers on Chronic, Stable Antipsychotic Regimens","enrollment":40},{"nctId":"NCT00890175","phase":"PHASE1","title":"Staccato Loxapine Pulmonary Safety in Patients With Asthma","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2009-05","conditions":"Asthma","enrollment":52},{"nctId":"NCT00873769","phase":"PHASE1","title":"Staccato Loxapine PK in Smokers and Nonsmokers","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2009-04","conditions":"Smoking, Cigarette","enrollment":35},{"nctId":"NCT00889837","phase":"PHASE1","title":"Staccato Loxapine Pulmonary Safety in Patients With COPD","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":61,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ADASUVE"],"phase":"phase_3","status":"active","brandName":"Inhaled Loxapine","genericName":"Inhaled Loxapine","companyName":"Alexza Pharmaceuticals, Inc.","companyId":"alexza-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhaled loxapine is a rapid-acting antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce acute agitation. Used for Acute agitation associated with schizophrenia or bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}